Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H11N2O2.Na |
Molecular Weight | 274.2498 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].O=C1NC(C(=O)[N-]1)(C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=FJPYVLNWWICYDW-UHFFFAOYSA-M
InChI=1S/C15H12N2O2.Na/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12;/h1-10H,(H2,16,17,18,19);/q;+1/p-1
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C15H12N2O2 |
Molecular Weight | 252.268 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/8981053Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020450s020lbl.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8981053
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020450s020lbl.pdf
Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX® (fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na+ channels in the plasma membrane of neurons undergoing seizure activity.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4187 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8981053 |
10.4 µM [EC50] | ||
Target ID: CHEMBL5163 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8981053 |
52.5 µM [EC50] | ||
Target ID: CHEMBL5202 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8981053 |
20.0 µM [EC50] | ||
Target ID: CHEMBL1845 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8981053 |
19.9 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DILANTIN-125 Approved UseDilantin (phenytoin) is indicated for the control of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures Launch Date-5.36025596E11 |
|||
Primary | CEREBYX Approved UseCEREBYX is indicated for the control of generalized tonic-clonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery. CEREBYX can also be substituted, short-term, for oral phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. CEREBYX must not be given orally. Launch Date8.3911678E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.176 μg/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYTOIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
32.172 μg × h/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYTOIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15.49 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHENYTOIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
600 mg single, oral Highest studied dose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: |
unhealthy, 31 years n = 15 Health Status: unhealthy Condition: epilepsy Age Group: 31 years Sex: M+F Population Size: 15 Sources: |
|
20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Co-administed with:: glibenclamide(500 mg) Sources: |
unhealthy, 41 years n = 1 Health Status: unhealthy Age Group: 41 years Sex: F Population Size: 1 Sources: |
Other AEs: Sinus bradycardia, Hypotension... Other AEs: Sinus bradycardia (1 patient) Sources: Hypotension (severe, 1 patient) |
5 g single, oral Overdose |
unhealthy, 49 years n = 1 Health Status: unhealthy Age Group: 49 years Sex: M Population Size: 1 Sources: |
Other AEs: Acute respiratory failure... |
60 mg/kg multiple, intravenous (total) Overdose Dose: 60 mg/kg Route: intravenous Route: multiple Dose: 60 mg/kg Sources: |
unhealthy, 7 years n = 1 Health Status: unhealthy Age Group: 7 years Sex: M Population Size: 1 Sources: |
Other AEs: Encephalopathy... |
2 g single, oral Overdose Dose: 2 g Route: oral Route: single Dose: 2 g Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Nystagmus, Ataxia... Other AEs: Nystagmus (grade 5) Sources: Ataxia (grade 5) Dysarthria (grade 5) Tremor (grade 5) Hyperreflexia (grade 5) Lethargy (grade 5) Slurred speech (grade 5) Blurred vision (grade 5) Nausea (grade 5) Vomiting (grade 5) |
10 mg/kg single, intramuscular (starting) Dose: 10 mg/kg Route: intramuscular Route: single Dose: 10 mg/kg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Hypotension, Cardiac arrhythmias... Other AEs: Hypotension (severe) Sources: Cardiac arrhythmias |
10 mg/kg single, intravenous (starting) Dose: 10 mg/kg Route: intravenous Route: single Dose: 10 mg/kg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Hypotension, Cardiac arrhythmias... Other AEs: Hypotension (severe) Sources: Cardiac arrhythmias |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Sinus bradycardia | 1 patient | 20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Co-administed with:: glibenclamide(500 mg) Sources: |
unhealthy, 41 years n = 1 Health Status: unhealthy Age Group: 41 years Sex: F Population Size: 1 Sources: |
Hypotension | severe, 1 patient | 20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Co-administed with:: glibenclamide(500 mg) Sources: |
unhealthy, 41 years n = 1 Health Status: unhealthy Age Group: 41 years Sex: F Population Size: 1 Sources: |
Acute respiratory failure | 1 patient | 5 g single, oral Overdose |
unhealthy, 49 years n = 1 Health Status: unhealthy Age Group: 49 years Sex: M Population Size: 1 Sources: |
Encephalopathy | 1 patient | 60 mg/kg multiple, intravenous (total) Overdose Dose: 60 mg/kg Route: intravenous Route: multiple Dose: 60 mg/kg Sources: |
unhealthy, 7 years n = 1 Health Status: unhealthy Age Group: 7 years Sex: M Population Size: 1 Sources: |
Ataxia | grade 5 | 2 g single, oral Overdose Dose: 2 g Route: oral Route: single Dose: 2 g Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Blurred vision | grade 5 | 2 g single, oral Overdose Dose: 2 g Route: oral Route: single Dose: 2 g Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Dysarthria | grade 5 | 2 g single, oral Overdose Dose: 2 g Route: oral Route: single Dose: 2 g Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Hyperreflexia | grade 5 | 2 g single, oral Overdose Dose: 2 g Route: oral Route: single Dose: 2 g Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Lethargy | grade 5 | 2 g single, oral Overdose Dose: 2 g Route: oral Route: single Dose: 2 g Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Nausea | grade 5 | 2 g single, oral Overdose Dose: 2 g Route: oral Route: single Dose: 2 g Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Nystagmus | grade 5 | 2 g single, oral Overdose Dose: 2 g Route: oral Route: single Dose: 2 g Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Slurred speech | grade 5 | 2 g single, oral Overdose Dose: 2 g Route: oral Route: single Dose: 2 g Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Tremor | grade 5 | 2 g single, oral Overdose Dose: 2 g Route: oral Route: single Dose: 2 g Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Vomiting | grade 5 | 2 g single, oral Overdose Dose: 2 g Route: oral Route: single Dose: 2 g Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Cardiac arrhythmias | 10 mg/kg single, intramuscular (starting) Dose: 10 mg/kg Route: intramuscular Route: single Dose: 10 mg/kg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
Hypotension | severe | 10 mg/kg single, intramuscular (starting) Dose: 10 mg/kg Route: intramuscular Route: single Dose: 10 mg/kg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Cardiac arrhythmias | 10 mg/kg single, intravenous (starting) Dose: 10 mg/kg Route: intravenous Route: single Dose: 10 mg/kg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
Hypotension | severe | 10 mg/kg single, intravenous (starting) Dose: 10 mg/kg Route: intravenous Route: single Dose: 10 mg/kg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/15961125/ Page: 6.0 |
weak | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15933229/ Page: 7.0 |
yes [IC50 145 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15933229/ Page: 7.0 |
yes [IC50 280 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/15933229/ Page: 7.0 |
yes [IC50 607 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/9606477 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/9332469/ |
yes | likely (co-administration study) Comment: See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page=10 Sources: https://pubmed.ncbi.nlm.nih.gov/9332469/ |
||
Sources: https://pubmed.ncbi.nlm.nih.gov/15247556/ |
yes | likely (co-administration study) Comment: See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page=10 Sources: https://pubmed.ncbi.nlm.nih.gov/15247556/ |
||
Sources: https://pubmed.ncbi.nlm.nih.gov/26721703/ Page: 46.0 |
yes | likely (co-administration study) Comment: See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page=11 Sources: https://pubmed.ncbi.nlm.nih.gov/26721703/ Page: 46.0 |
||
Sources: https://pubmed.ncbi.nlm.nih.gov/15247556/ |
yes | likely (co-administration study) Comment: See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page=9 Sources: https://pubmed.ncbi.nlm.nih.gov/15247556/ |
||
Sources: https://pubmed.ncbi.nlm.nih.gov/9606477 |
yes | likely (co-administration study) Comment: See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page=11 Sources: https://pubmed.ncbi.nlm.nih.gov/9606477 |
||
yes | yes (co-administration study) Comment: mean AUC(0-24) of losartan was insignificantly increased by 17% when losartan was coadministered with phenytoin. See more on https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page=9 Sources: https://pubmed.ncbi.nlm.nih.gov/12235444/ |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/15961125/ Page: 6.0 |
no | |||
Page: 8.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8819299/ Page: 7.0 |
yes | |||
yes | likely (co-administration study) Comment: See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page=9 Sources: https://pubmed.ncbi.nlm.nih.gov/11038165/ |
|||
yes | yes (co-administration study) Comment: Coadministration of losartan had no effect on the pharmacokinetics of phenytoin. See more on https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page8 Page: 8.0 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
The influence of aldosterone and anticonvulsant drugs on electroencephalographic and clinical disturbances induced by the spirolactone derivative, potassium canrenoate. | 1975 Jan |
|
Procainamide and phenytoin. Comparative study of their antiarrhythmic effects at apparent therapeutic plasma levels. | 1975 Jul |
|
Spasticity due to phenytoin toxicity. | 1979 Mar 10 |
|
Cognitive dysfunction induced by phenytoin and valproate in rats: effect of nitric oxide. | 1999 Jul |
|
Retro-peritoneal cystic lymphangioma in association with fetal hydantoin syndrome. | 1999 Mar-Apr |
|
Fetal hydantoin syndrome with rheumatic valvular heart disease. | 1999 Mar-Apr |
|
Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. | 1999 Oct |
|
Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene. | 1999 Sep |
|
[Acute liver failure by diphenylhydantoin]. | 2000 |
|
[Phenytoin-induced hypersensitivity reaction with liver failure]. | 2000 Apr 13 |
|
Protection from phenytoin-induced cognitive deficit by Bacopa monniera, a reputed Indian nootropic plant. | 2000 Aug |
|
Acute fulminant hepatic failure in a woman treated with phenytoin and trimethoprim-sulfamethoxazole. | 2000 Dec |
|
Phenytoin, midazolam, and naloxone protect against fentanyl-induced brain damage in rats. | 2000 Dec |
|
Effects of anticonvulsants on local anaesthetic-induced neurotoxicity in rats. | 2000 Feb |
|
A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy. | 2000 Feb |
|
Felbamate in experimental model of status epilepticus. | 2000 Feb |
|
Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. | 2000 Feb 28 |
|
Images in clinical medicine. Gingival hyperplasia induced by phenytoin. | 2000 Feb 3 |
|
Immunolocalizaiton of c-Myc and bcl-2 proto-oncogene products in gingival hyperplasia induced by nifedipine and phenytoin. | 2000 Jan |
|
An embryoprotective role for glucose-6-phosphate dehydrogenase in developmental oxidative stress and chemical teratogenesis. | 2000 Jan |
|
Cerebral edema with herniation during acetaminophen-induced fulminant hepatic failure. | 2000 Jul |
|
Seizure-inducing paradoxical reaction to antiepileptic drugs. | 2000 Jun |
|
Temporal and spatial expression of Hoxa-2 during murine palatogenesis. | 2000 Jun |
|
Gabapentin prophylaxis of clozapine-induced seizures. | 2000 Mar |
|
Purple glove syndrome caused by oral administration of phenytoin. | 2000 Nov |
|
Activation of cytochrome P450 gene expression in the rat brain by phenobarbital-like inducers. | 2000 Sep |
|
Drugs for discoid lupus erythematosus. | 2001 |
|
II. An altered proliferation response due to the anticonvulsant phenytoin (PHT) in epileptic patients. | 2001 |
|
I. The modulatory effect in genotoxic responses due to age and duration of PHT-therapy in epileptic patients. | 2001 |
|
Performance characteristics of four free phenytoin immunoassays. | 2001 Apr |
|
Rocuronium-induced neuromuscular blockade is affected by chronic phenytoin therapy. | 2001 Apr |
|
Stereoselective determination of p-hydroxyphenyl-phenylhydantoin enantiomers in rat liver microsomal incubates by reversed-phase high-performance liquid chromatography using beta-cyclodextrin as chiral mobile phase additives. | 2001 Apr |
|
Cardiac arrest after fast intravenous infusion of phenytoin mistaken for fosphenytoin. | 2001 Feb |
|
Antiepileptic drug withdrawal in patients with temporal lobe epilepsy undergoing presurgical video-EEG monitoring. | 2001 Feb |
|
Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses. | 2001 Feb |
|
Glutamate receptor antagonists differentially affect the protective activity of conventional antiepileptics against amygdala-kindled seizures in rats. | 2001 Feb |
|
Phenytoin intoxication induced by fluvoxamine. | 2001 Feb |
|
The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. | 2001 Feb |
|
[Febrile convulsions, Treatment and prognosis]. | 2001 Feb 19 |
|
Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma. | 2001 Jan |
|
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. | 2001 Jan |
|
Electrophysiological and pharmacological properties of the human brain type IIA Na+ channel expressed in a stable mammalian cell line. | 2001 Jan |
|
Hair analysis for pharmaceutical drugs. I. Effective extraction and determination of phenobarbital, phenytoin and their major metabolites in rat and human hair. | 2001 Jan |
|
Ritonavir-induced carbamazepine toxicity. | 2001 Jan |
|
Effects of antiepileptic drugs on rat platelet aggregation: ex vivo and in vitro study. | 2001 Jan |
|
[Lamotrigine in refractory partial and general epilepsies]. | 2001 Jan 1-15 |
|
Volume-selective proton MR spectroscopy for in-vitro quantification of anticonvulsants. | 2001 Mar |
|
Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. | 2001 Mar |
|
Phenytoin-induced cleft palate: evidence for embryonic cardiac bradyarrhythmia due to inhibition of delayed rectifier K+ channels resulting in hypoxia-reoxygenation damage. | 2001 Mar |
|
Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus. | 2017 Jun |
Sample Use Guides
Dilantin-125® (Phenytoin Oral Suspension, USP), each 5 ml of suspension contains 125 mg of phenytoin: Patients who have received no previous treatment may be started on one teaspoonful (5 mL) of Dilantin-125 Suspension three times daily, and the dose is then adjusted to suit individual requirements. An increase to five teaspoonfuls daily may be made, if necessary.
CEREBYX® (fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. 1.5 mg of fosphenytoin sodium is equivalent to
1 mg phenytoin sodium, and is referred to as 1 mg phenytoin sodium equivalents (PE). CEREBYX should be used only when oral phenytoin administration is not possible.
Dosage (Status Epilepticus): The loading dose of CEREBYX is 15 to 20 mg PE/kg administered at 100 to 150 mg PE/min.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27522920
Exposure of human adult keratinocytes (HaCaT cells) for 48 h to alkyd nanoemulsions producing phenytoin concentrations of 3.125-200 μg/mL resulted in relative cell viability readings using tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide of 100% confirming nontoxicity and suggesting cell proliferation activity.
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 00:04:03 UTC 2023
by
admin
on
Thu Jul 06 00:04:03 UTC 2023
|
Record UNII |
4182431BJH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C264
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
||
|
NCI_THESAURUS |
C93038
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
||
|
CFR |
21 CFR 522.900
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4182431BJH
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
PRIMARY | |||
|
657302
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
PRIMARY | |||
|
71227
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
PRIMARY | RxNorm | ||
|
630-93-3
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
PRIMARY | |||
|
4182431BJH
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
PRIMARY | |||
|
DBSALT000139
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
PRIMARY | |||
|
SUB03787MIG
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
PRIMARY | |||
|
PHENYTOIN SODIUM
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
PRIMARY | Description: A white powder; odourless. Solubility: Soluble in water, giving a slightly turbid solution owing to partial hydrolysis; soluble in ethanol (~750 g/l) TS; practicallyinsoluble in ether R. Category: Anticonvulsant. Storage: Phenytoin sodium should be kept in a tightly closed container. Additional information: Phenytoin sodium is somewhat hygroscopic and on exposure to air gradually absorbs carbon dioxide. Definition: Phenytoin sodium contains not less than 98.5% and not more than 101.0% of C15H11N2NaO2, calculated withreference to the dried substance. | ||
|
1535507
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
PRIMARY | |||
|
211-148-2
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
PRIMARY | |||
|
CHEMBL16
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
PRIMARY | |||
|
C48011
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
PRIMARY | |||
|
100000089972
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
PRIMARY | |||
|
M8703
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
PRIMARY | Merck Index | ||
|
757274
Created by
admin on Thu Jul 06 00:04:03 UTC 2023 , Edited by admin on Thu Jul 06 00:04:03 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
SUB_CONCEPT->SUBSTANCE | |||
|
LABELED -> NON-LABELED | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
PARENT -> SALT/SOLVATE | |||
|
SUB_CONCEPT->SUBSTANCE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |